Cowen analyst Yaron Werber assumed coverage of Exelixis with an Outperform rating and $29 price target. Werber noted that, “after strong growth, Cabometyx is facing intense competition that may pressure sales,” but the analyst anticipates positive Phase 3 data from CHECKMATE-9ER in the second half of 2019 re-accelerating growth. Werber also believes that “recent strong bids for oncology companies may put Exelixis at play for takeout.”
https://thefly.com/landingPageNews.php?id=2869891
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.